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http://www.biomedcentral.com/1746-6148/10/296RESEARCH ARTICLE Open AccessProgesterone receptor isoform A may regulate
the effects of neoadjuvant aglepristone in canine
mammary carcinoma
Silvia Guil-Luna1*, Jan Stenvang2, Nils Br?nner 2, Francisco Javier De Andr?s 3, Eva Roll?n 4, V?ctor Domingo 5,
Raquel S?nchez-C?spedes 1, Yolanda Mill?n 1 and Juana Mart?n de las Mulas 1Abstract
Background: Progesterone receptors play a key role in the development of canine mammary tumours, and recent
research has focussed on their possible value as therapeutic targets using antiprogestins. Cloning and sequencing
of the progesterone receptor gene has shown that the receptor has two isoforms, A and B, transcribed from a
single gene. Experimental studies in human breast cancer suggest that the differential expression of progesterone
receptor isoforms has implications for hormone therapy responsiveness. This study examined the effects of the
antiprogestin aglepristone on cell proliferation and mRNA expression of progesterone receptor isoforms A and B in
mammary carcinomas in dogs treated with 20 mg/Kg of aglepristone (n = 22) or vehicle (n = 5) twice before surgery.
Results: Formalin-fixed, paraffin-embedded tissue samples taken before and after treatment were used to analyse total
progesterone receptor and both isoforms by RT-qPCR and Ki67 antigen labelling. Both total progesterone receptor and
isoform A mRNA expression levels decreased after treatment with aglepristone. Furthermore, a significant decrease in
the proliferation index (percentage of Ki67-labelled cells) was observed in progesterone-receptor positive and isoform-A
positive tumours in aglepristone-treated dogs.
Conclusions: These findings suggest that the antiproliferative effects of aglepristone in canine mammary carcinomas are
mediated by progesterone receptor isoform A.
Keywords: Canine mammary carcinoma, Progesterone receptor, Isoforms, Aglepristone, Hormone treatmentBackground
Epidemiological and clinical data indicate that progesterone
has proliferative effects on normal and neoplastic canine
mammary epithelium [1]. Immunohistochemical (IHC)
labelling at diagnosis has identified approximately two
thirds of canine mammary carcinomas as progesterone
receptor (PR) positive [2]. Moreover, neoadjuvant treatment
with the antiprogestin aglepristone has been found to
decrease cell proliferation in PR positive canine mammary
carcinomas [3]. Aglepristone is currently used in clinical
practice to induce abortion and treat pyometra, as well
in the treatment of proliferative progesterone-dependent* Correspondence: v22gulus@uco.es
1Department of Comparative Pathology, Veterinary Faculty, University of
C?rdoba, Edificio de Sanidad Animal. Campus de Rabanales. Carretera de
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unless otherwise stated.diseases such as mammary fibroadenomatous hyperplasia
in queens and vaginal tumours in bitches.
Like its human counterpart, canine PR exists as two
isoforms: PR isoform A (PRA) and PR isoform B (PRB),
which are transcribed from a single gene under the
control of different promoters [4]. Under physiological
conditions, normal human breast tissue expresses
both PRA and PRB at equimolar levels [5]. However,
an altered PRA/PRB ratio is often associated with
breast carcinogenesis, PRA predominating over PRB
in benign and malignant human breast tumours [5].
Findings in dogs remain controversial, due to the paucity
of research and the limited number of samples analysed.
Western blot analysis of normal and tumoural mammary
glands from six female dogs (two in metoestrus, two
in anoestrus and two after prolonged treatment with
progestins) showed that PRA was either equimolar orl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of PRB was recorded in only one case [4]. Moreover,
the same technique has revealed predominant staining
for PRA with less intense staining for PRB in two
normal canine mammary glands, three hyperplasias and
three mammary carcinomas [6].
Despite their structural similarities, human PRA and
PRB have been shown to have different functions, in that
they regulate different subsets of genes [7]. In human
breast cancer, carcinomas with higher levels of PRA than
PRB were inhibited by antiprogestins, whereas carcinomas
with high levels of PRB displayed no response to endocrine
treatment [7]. Accordingly, it has been suggested that the
relative proportion of PR isoforms A and B might affect
the prognosis and thus influence therapeutic decisions [5].
We have previously shown that 1) neoadjuvant treatment
with aglepristone decreases cell proliferation in PR positive
carcinomas [3], and 2) PRA and PRB mRNA expression
can be analysed in formalin-fixed, paraffin-embedded
canine mammary gland tissue samples by RT-qPCR [8].
This study sought to examine the link between the effects
of aglepristone on the proliferation index and mRNA
expression of PRA and PRB in canine mammary carcin-
omas. IHC data of PR expression in the cases under study
have been previously published [3].
Methods
Tissue samples and clinical data
Formalin-fixed paraffin-embedded (FFPE) tissue samples
from 27 canine mammary carcinomas were taken from
27 dogs randomly recruited between 2008 and 2010 for
a pharmacodynamic study [3]. Dogs were aged 5 to 16,
of both pure (n = 14) and mixed (n = 13) breeds, and
at all phases of the oestrous cycle except oestrus (23
anoestrus, 3 dioestrus and 1 proestrus) as determined
by vaginal cytology. Carcinomas were at three clinical
stages: I (n = 19), II (n = 6) and III (n = 2). None of
the dogs had lung metastases (as determined by two
thoracic radiographs).
Treatment protocol
All owners gave their informed consent for inclusion of
their pets in this study, which did not require approval
by the Bioethics Committee of the University of C?rdoba
(RD53/2013). All dogs received 2 subcutaneous injectionsTable 1 Primer sequences for RT-qPCR amplification
Primer Forward
PR 5′-GGCTTGCCGCAGGTGTACCA-3′
PRB 5′-CCCGGGCGGATCCGAGACT-3′
HPTR1 5′-TGCAGACTTTGCTTTCCTTGGTCA-3′
RPL32 5′-GGCTGCCCTCAGACCTCTGGT -3′
PR: Progesterone receptor; PRB: Progesterone receptor isoform B; HPTR1:Hypoxanthof 20 mg/kg of aglepristone (Alizine, Virbac, France)
(n = 22 dogs) or vehicle (n = 5 dogs) on days 1 and 7,
Surgery was performed on day 15 [3]. To analyse the
effects of aglepristone, a core biopsy was taken on
day 1 prior to the first injection of aglepristone or oil
vehicle, and the biopsied area was marked with suture
thread in order to avoid variability in subsequent
studies. Finally, all patients underwent complete surgical
excision of the tumour on day 15 [3]. Fixation time ranged
from 24 to 48 hours, and paraffin blocks were stored
at 4?C. Histological tumour types [9] included 14
complex carcinomas, 6 simple carcinomas, 5 carcinomas
in benign tumour, 1 carcinosarcoma and 1 squamous cell
carcinoma.
RT-qPCR analysis
PR expression was analysed before and after treatment
(treated and control samples). RNA was isolated using
the RNase FFPE kit (Qiagen, Copenhagen, Denmark) in
accordance with manufacturers ? recommendations. RNA
yields and purity were determined by spectrophoto-
metric absorbance at 260 nm (A260) measured with a
NanoDrop? ND-1000 spectrophotometer (Thermo Scientific,
Wilmington, DE, USA). A ratio of absorbance at 260 nm
and 280 nm 1.8-2.0 was accepted as ? pure ? . The integrity
of total RNA was checked by denaturing agarose gel
electrophoresis and ethidium bromide staining showing
the respective mRNAs as sharp bands.
Extracted RNA was stored at −80?C until use. It was
then amplified and melting-curve analysis was carried
out using the LightCycler? 480 Real-Time PCR System.
One-step RT-qPCR was performed using the QuantiFast?
SYBR? Green RT-PCR (Qiagen, Copenhagen, Denmark), fol-
lowing a previously-described protocol [8]. Canine-specific
primers for PR gene were designed specifically to target the
region of canine isoform B and the region common to both
isoforms (total PR) using Primer3Plus and based on the
reported canine PR sequence (NM_001003074) [4]. Primers
flanking one intron were chosen wherever possible and their
specificity was checked by performing a BLAST? search
showing 100% homology to target genes [8]. Moreover,
primers were designed to produce an amplicon smaller
than 100 bp in order to ensure that the sequences were
unique for the template (Table 1, Additional file 1). PR ex-
pression was normalised against two canine housekeepingPrimer Reverse Product length
5′- ACTGTGGGCTCTGGCTGGCA-3′ 73 bp
5′-GTGCAGCGGCCCTCGGTC-3′ 86 bp
5′-TCGAGGGGTCCTTTTCACCAGCA -3′ 81 bp
5′-TCGGTCTGACTGGTGCCGGA -3′ 79 bp
ine phosphoribosyl-transferase 1; RPL32: Canine ribosomal protein L32.
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NM_001003357.1) and canine ribosomal protein L32
(RPL32, NM_001252169.1). Forward and reverse primer
sequences for PR gene and housekeeping genes are
summarised in Table 1. Reverse transcription negative con-
trols and non-template controls were included, and PCR
products were separated in a 3% agarose gel and visualised
by ethidium bromide staining.
For relative quantitation, target gene signals were
normalised against those of the two selected house-
keeping genes using the comparative Ct method
(ΔΔCt) following Schmittgen et al. [10]. RT-qPCR
data was presented as 2-ΔCt where ΔCt = CtTARGET ?
CtRPL32/HPTR1, and CtRPL32/HPTR1 is the geometric
mean of the Ct values of the two housekeeping genes for
each sample. PRA levels were calculated by subtracting
the relative amount of PRB from that of total PR, as
reported in studies in humans [11].
Amplification plots derived from melting-curve analyses
displayed satisfactory amplification curves, single-peak
melting curves and adequate melting temperatures.
For PRB, however, melting-curve analysis revealed
one major sharp peak but also additional extra minor
peaks at lower Tm consistent with the agarose gel [8].
Concordance between data of immunohistochemistry
and gene expression data was calculated using Cohen? s
Kappa statistics.
Proliferation index (PI)
The proliferation index was analysed by IHC in all
samples obtained before and after treatment. The
monoclonal mouse anti-human Ki67 antigen (clone
MIB-1) isotype IgG1 (Dako, Barcelona, Spain) diluted
1:75, and the ABC method were applied as described
previously [3]. Briefly, the slides were incubated in a
water bath at 95-99?C with 0.01 M citrate buffer for
40 minutes at pH 6.0 for antigen retrieval. After cooling,
sections were covered with 10% normal goat serum in
PBS for 30 minutes before incubation with the primaryFigure 1 Simple tubular mammary carcinoma. Inmunohistochemical PR
PR + tumour at day 1 (A) and a PR - tumour at day 15 (B) [3]. ABC immunoantibody for 18 hours. The avidin-biotin-peroxidase
complex was applied for 1 hour at room temperature. The
chromogen, 3,3-diaminobenzidine tetra-hydrochloride
(Sigma, Saint Louis, USA) diluted 0.035% in 0.05 M Tris
containing 0.3% of hydrogen peroxide was applied to
slides for 1 min at 20-22?C. Lymph node was used as
positive control; for the negative control, the primary
antibody was replaced by IgG1 at the same dilution as
the primary antibody. Positive and negative tumour
cells were counted with a pen tablet (Volito 2, Wacom
Europe GmbH, Krefeld, Germany). PI was expressed as
the percentage of positive tumour cells with respect to the
total number of cells; counts were performed by two
pathologists to ensure uniformity. A minimum of 1000
cells were counted per case.
Statistical analysis
For statistical data evaluation, the software GraphPad
PRISM 5 version 5.01 (GraphPad Software Inc, San
Diego, CA, USA). was used. Continuous variables were
subjected to the D ?Agostino-Pearson test to determine
sample distribution. Differences between the means of
aglepristone-treated tumours before and after treatment
were assessed by paired t-test when data were normally
distributed, and otherwise by the Wilcoxon test. The
agreement between RT-qPCR and IHC findings was
estimated using Cohen ? s κ coefficient. A P value < 0.05
was regarded as statistically significant.
Results
PR protein expression correlates with mRNA expression
The PR positive-status cut-off value on RT-qPCR was
set at 0.04. The concordance rates at this cut-off were
the highest for IHC assay (Figure 1 [3]) with a Kappa
index of 0.6 (Figure 2).
PR, PRA and PRB mRNA expression levels
Before treatment, PR mRNA values ranged from 0 to
0.27 (0.07 ? 0.01) while after treatment they lay betweenlabelling is seen in the nuclei of tumour epithelial cells. A strong
histochemical method. Bar = 10 μm.
Figure 2 Comparison of RT-qPCR values versus immunohistochemical assessment in the 27 samples. The Y-axis shows PR mRNA
expression values and the X-axis the PR (+) and (−) samples by IHC. The cut-off for PR (+) status by RT-qPCR is indicated by the horizontal broken
line. Black diamonds show the discrepancy between the two methods.
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results, 60% of tumours in the control group (n = 3, 2
complex and 1 carcinoma in benign tumour) and 55% of
tumours in the experimental group (n = 12, 8 complex, 3
carcinomas in benign tumour and 1 simple carcinoma)
were classed as PR-positive prior to treatment. Complex
carcinomas and carcinomas in benign tumour had similar
PR mRNA (0.075 and 0.069, respectively) whereas simple
carcinomas displayed the lowest levels (0.016, p = 0.002
and p = 0.04, respectively). A significant decrease in
PR mRNA expression was noted after treatment in
PR-positive tumours in the aglepristone-treated group
alone (p = 0.001) (Table 2), whereas tumours in the control
group and PR-negative tumours in the aglepristone-treated
group exhibited no significant change. Overall, PR expres-
sion in PR-positive tumours in the aglepristone-treated
group was reduced 2.28-fold due to treatment.
Before treatment, PRA mRNA values ranged from 0 to
0.21 (0.046 ? 0.1) and PRB mRNA values from 0 to 0.06
(0.02 ? 0.002). The figures after treatment were 0.01 to
0.11 (0.03 ? 0.03) for PRA and 0 to 0.06 (0.01 ? 0.01) for
PRB. In 48% of samples (n = 13, 8 complex carcinomas, 4
carcinomas in benign tumour and 1 simple carcinoma),
PRA mRNA expression was between 3 and 10 times higher
than PRB mRNA expression on day 1; PRA expression wasTable 2 Total PR mRNA expression before and after
treatment as a function of PR status on day 1
Median ? SD of PR expression
(2^-ΔCt)
PR status at day 1 Day 1 Day 15
Control group PR+ 0.05 ? 0.02 0.04 ? 0.06
PR- 0.02 ? 0.00 0.03 ? 0.00
Treated group PR+ 0.09 ? 0.07 0.03 ? 0.03*
PR- 0.02 ? 0.01 0.03 ? 0.05
PR: Progesterone receptor; SD: Standard deviation; PR+: Progesterone receptor
positive; PR-: Progesterone receptor negative. *P < 0.05.also significantly higher than PRB expression in 80%
of tumours (n = 4) in the control group and 82% in the
experimental group (n = 18) (P = 0.003). After treatment, a
significant decrease in PRA expression (2-fold changes
with respect to pre-treatment samples) was observed in
PRA-positive tumours in the aglepristone-treated group
alone (p = 0.001) (Table 3). PRA-negative tumours and tu-
mours in the control group showed no significant changes
after treatment. PRB expression was not affected by agle-
pristone treatment in any sample (Table 4). No statistical
differences were observed as a function of oestrus phase
or clinical stage, or between levels of PR and PR isoform
expression by RT-qPCR.
Proliferation index and PR, PRA and PRB expression levels
A significant decrease in PI after aglepristone treatment
was observed in PR- and PRA-positive tumours in the
treated group alone (P = 0.007, P = 0.01, respectively)
(Figures 3 and 4). A reduction of ≥ 20% in the PI was re-
corded in 62% of these cases (n = 8). No significant
changes in the PI were found as a function of PRB expres-
sion (Figure 4). Moreover, no statistically- significant dif-
ferences in PI were observed as a function of histological
tumour type or oestrus phase.Table 3 PRA mRNA expression before and after treatment
as a function of PRA status on day 1
Median ? SD of PRA expression
(2^Δ-Ct)
PRA status at day 1 Day 1 Day 15
Control group PRA+ 0.05 ? 0.02 0.08 ? 0.06
PRA- 0.01 ? 0.01 0.03 ? 0.00
Treated group PRA+ 0.08 ? 0.05 0.04 ? 0.02*
PRA- 0.01 ? 0.01 0.02 ? 0.04
PRA: Progesterone receptor isoform A; SD: Standard deviation; PRA+:
Progesterone receptor isoform A positive; PRA-: Progesterone receptor isoform
A negative. *P < 0.05.
Table 4 PRB mRNA expression before and after treatment
as a function of PRB status on day 1
Median ? SD of PRB expression
(2^-ΔCt)
PRB status at day 1 Day 1 Day 15
Control group PRB+ 0.014 ? 0.01 0.010 ? 0.02
PRB- 0.007 ? 0.00 0.007 ? 0.001
Treated group PRB+ 0.014 ? 0.01 0.011 ? 0.01
PRB- 0.006 ? 0.002 0.006 ? 0.003
PRB: Progesterone receptor isoform B; SD: Standard deviation; PRB+:
Progesterone receptor isoform B positive; PRB-: Progesterone receptor isoform
B negative.
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These findings confirm previous reports indicating a
direct link between PR labelling and the antiproliferative
effect of aglepristone in canine mammary carcinoma [3],
and suggest that this effect might be mediated by PRA.
Results for PR expression levels in canine mammary
tumours are in agreement with those previously reported
using IHC [3]. The epitope detected by the antibody
clone used for this study (extreme C-terminus of human
PR) is identical to that of canine PR, and can thus be used
with dogs (http://blast.ncbi.nlm.nih.gov). Furthermore,
IHC and RT-qPCR techniques demonstrated a high level
of agreement for PR expression, as reported in human
studies [12]. Complex carcinomas and carcinomas in
benign tumour displayed higher PR expression than
simple carcinomas, but no significant differences in
PR expression were observed with either technique as
a function of oestrus phase. Slight differences in the
intensity of PR labelling by IHC have been reported in
normal mammary gland (moderate to strong during
oestrus and dioestrus compared with anoestrus) but the
small number of animals and the lack of proestrus
samples were constraints in this study [13].
The clinical impact of these findings relates to the
potential use of antiprogestins in the treatment of breastFigure 3 Simple solid mammary carcinoma. Immunohistochemical Ki67
(A) and at day 15 (B). A significant decrease of Ki67 labelling is observed at d
method. Bar = 10 μm.cancer and to the potential prognostic value of PR isoform
expression. In women, more than 70% of breast cancers
express oestrogen receptors (ER) and PR, and are thus
eligible for adjuvant endocrine therapy [5]. This therapy is
designed to target ER either by using ER modulators or by
inhibiting the endogenous synthesis of 17β-estradiol with
aromatase inhibitors. However, recent research also
points to PR as a therapeutic target [5,7]. In this
respect, antiprogestins ? either alone or in conjunction
with antiestrogens ? have been shown to exert an
inhibitory effect in various experimental breast cancer
models [7,14]. Around 75% of canine mammary
carcinomas are PR positive [2] but, unlike in women,
adjuvant endocrine treatment aimed at blocking the
PR is not currently used. The dog has been proposed
as a natural model for human breast cancer [15]. At
the same time, dogs with mammary cancer may bene-
fit from these findings, since tumours with PR and PRA
expression at day 1 exhibited a significant decrease in the
proliferation index after aglepristone treatment [3]. In
human breast cancer, a number of studies have associated
the inhibitory effect of antiprogestins with PRA but not
with PRB expression [7]. A down-regulation of PRA has
been reported, as in canine carcinomas, and has been
cited as a possible explanation for the antiproliferative
effects of antiprogestins. The absence of significant
changes in PI and PRB mRNA levels in the tumours ana-
lysed here suggests that PRA mediates the antiproliferative
effect of aglepristone, thus highlighting the differential
roles of PRA and PRB in the canine mammary gland.
These findings therefore suggest that the differential
expression of PRA and PRB is critical for an appropriate
therapeutic response to antiprogestins. This appears to be
the first evidence of a link between PR isoform expression
and proliferation in canine mammary carcinomas.
In the normal human breast, PRA and PRB are generally
expressed at similar levels. However, in breast cancers,
their ratio is deregulated, with a predominance of PRAlabelling is seen in the nuclei of tumour epithelial cells at day 1
ay 15 in PR-positive treated carcinomas [3]. ABC immunohistochemical
Figure 4 (See legend on next page.)
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Figure 4 Proliferation index. Effect of aglepristone treatment on the percentage of Ki67-labelled cells in PR-positive treated (A), PR-negative
treated (B), PR-positive control (C), PR-negative control (D), PRA-positive treated (E), PRA-negative treated (F), PRA-positive control (G), PRA-negative
control (H), PRB-positive treated (I), PRB-negative treated (J), PRB-positive control (K), PRB-negative control (L) canine mammary carcinomas at day 1
and day 15. *P < 0.05.
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omas showed higher PRA than PRB expression regardless
of histological tumour type, oestrus phase and tumour
clinical stage. These results are in agreement with those
reported in human breast cancer as well as in the few
samples of mammary tumours studied in dogs [7,4,6].
Human studies suggest that elevated PRA expression is
generally associated with a poor prognosis, and there is
evidence that genetic predisposition to cancer develop-
ment due to mutations in BRCA1 orBRCA2 genes leads to
PRA overexpression, which may play a role in disease
progression [16,17]. Disrupted PRA/PRB expression
has been reported in endometrial cancers, and research
suggests that cancers with an elevated PRA/PRB ratio are
also associated with a poor prognosis [18]. However, the
mechanisms via which these PR isoforms contribute to
tumour genesis are not yet fully understood.
Limitations of the present study were the total number
of samples used and the balance between experimental
and control cases. Nevertheless, the findings provide
new insights regarding PR and PR isoform expression in
the context of hormone treatment. Further research
with a larger number of samples is required in order
to establish what triggers the mechanisms underlying
the antiproliferative effect of aglepristone, and to clarify
the specific role of each PR isoform.
Conclusions
Results showed that neoadjuvant treatment of canine
mammary carcinomas with the antiprogestin aglepristone
reduced cell proliferation in those tumours classed as
PR-positive by the RT-qPCR method. The fact that
aglepristone also exerted the same effect in PRA-positive
tumours and not in PRB-positive tumours, suggests that
the antiproliferative effect of aglepristone in canine
mammary carcinoma is probably mediated by PRA.
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